Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
Provided By GlobeNewswire
Last update: Jan 13, 2025
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
Read more at globenewswire.comNASDAQ:CADL (4/25/2025, 2:02:44 PM)
4.975
-0.03 (-0.5%)
Find more stocks in the Stock Screener
CADL Latest News and Analysis
2 days ago - ChartmillTop movers in Wednesday's after hours sessionAs the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
